Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H33NO4 |
Molecular Weight | 435.5552 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC1=CC=C(COC2=CC3=C(C=C2)C(C)=C(CN4CC(C4)C(O)=O)CC3)C(OC)=C1
InChI
InChIKey=QDDQIPUKAXBMBX-UHFFFAOYSA-N
InChI=1S/C27H33NO4/c1-4-5-19-6-7-22(26(12-19)31-3)17-32-24-10-11-25-18(2)21(9-8-20(25)13-24)14-28-15-23(16-28)27(29)30/h6-7,10-13,23H,4-5,8-9,14-17H2,1-3H3,(H,29,30)
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4333 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26239599 |
|||
Target ID: CHEMBL2274 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26239599 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
985 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
111 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.01 mg single, oral dose: 0.01 mg route of administration: Oral experiment type: SINGLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1166 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.025 mg 1 times / day multiple, oral dose: 0.025 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2260 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.05 mg 1 times / day multiple, oral dose: 0.05 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
262 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.025 mg single, oral dose: 0.025 mg route of administration: Oral experiment type: SINGLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
434 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.01 mg 1 times / day multiple, oral dose: 0.01 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4428 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.1 mg 1 times / day multiple, oral dose: 0.1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
507 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.05 mg single, oral dose: 0.05 mg route of administration: Oral experiment type: SINGLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18620 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.1 mg single, oral dose: 0.1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1967 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.01 mg single, oral dose: 0.01 mg route of administration: Oral experiment type: SINGLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
24527 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.025 mg 1 times / day multiple, oral dose: 0.025 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
48497 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.05 mg 1 times / day multiple, oral dose: 0.05 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4908 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.025 mg single, oral dose: 0.025 mg route of administration: Oral experiment type: SINGLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
9219 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.01 mg 1 times / day multiple, oral dose: 0.01 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
93517 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.1 mg 1 times / day multiple, oral dose: 0.1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
9530 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.05 mg single, oral dose: 0.05 mg route of administration: Oral experiment type: SINGLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
81.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.025 mg 1 times / day multiple, oral dose: 0.025 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
89 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.05 mg 1 times / day multiple, oral dose: 0.05 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
81.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.01 mg 1 times / day multiple, oral dose: 0.01 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
84.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25855155 |
0.1 mg 1 times / day multiple, oral dose: 0.1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CERALIFIMOD plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling. | 2010 Oct |
|
Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. | 2013 Jan |
|
Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm. | 2015 Sep |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
891859-12-4
Created by
admin on Sat Dec 16 08:11:57 GMT 2023 , Edited by admin on Sat Dec 16 08:11:57 GMT 2023
|
PRIMARY | |||
|
100000175793
Created by
admin on Sat Dec 16 08:11:57 GMT 2023 , Edited by admin on Sat Dec 16 08:11:57 GMT 2023
|
PRIMARY | |||
|
9772
Created by
admin on Sat Dec 16 08:11:57 GMT 2023 , Edited by admin on Sat Dec 16 08:11:57 GMT 2023
|
PRIMARY | |||
|
C171818
Created by
admin on Sat Dec 16 08:11:57 GMT 2023 , Edited by admin on Sat Dec 16 08:11:57 GMT 2023
|
PRIMARY | |||
|
11502996
Created by
admin on Sat Dec 16 08:11:57 GMT 2023 , Edited by admin on Sat Dec 16 08:11:57 GMT 2023
|
PRIMARY | |||
|
BZ2O8A84A4
Created by
admin on Sat Dec 16 08:11:57 GMT 2023 , Edited by admin on Sat Dec 16 08:11:57 GMT 2023
|
PRIMARY |
ACTIVE MOIETY